Congratulations to: Dr. Harriet Feilotter of Queen’s University and colleagues who have created the Implementation Laboratory (IL), a central lab that can advise Ontario hospitals on the best way to test tumours for cancer biomarkers. I2IS funding will help them generate more evidence for the use of the lab and design educational and clinical tools to help Ontario hospitals access it.
“Testing tumours for genetic mutations can lead to personalized cancer treatment, but hospitals are largely on their own to figure out how to do it. A centralized, standardized lab will improve how the province makes genetic research available to cancer patients.” – Dr. Harriet Feilotter
First round of Innovation to Implementation Supplement (I2IS) grants awarded to five promising research projects taking unique approaches to addressing cancer.
August 11, 2022, TORONTO – Five Ontario-based research projects will take the next step toward advancing cancer care in the province thanks to funding from the Ontario Institute for Cancer Research (OICR).
OICR is announcing the first round of recipients of its new Innovation to Implementation Supplement (I2IS), which aims to help discoveries in cancer overcome barriers to health system implementation. All five projects advance research programs that were previously funded by OICR within the past five years. The supplemental funding announced today completes the continuum for these projects, helping them build on their previous success and translate what they have already learned into real-world impact.
“With Ontario’s population aging and the number of cancer diagnoses on the rise, translational cancer research that makes a difference in people’s lives is more important than ever,” says OICR President and Scientific Director Dr. Laszlo Radvanyi. “OICR is proud to have supported these innovative projects over the past few years and we hope this new funding will give them an extra push to take the next step now and shape cancer care and policy in Ontario.”
Each of the five supported projects is led by experts in their field taking a unique approach to addressing cancer: